Evidence map›Paper›PMID 27091927›Full record

ArticleInfection and immunity2016

Toll-Like Receptor 4 Agonistic Antibody Promotes Host Defense against Chronic Pseudomonas aeruginosa Lung Infection in Mice.

Shigeki Nakamura, Naoki Iwanaga, Masafumi Seki, Kenji Fukudome, Kazuhiro Oshima, Taiga Miyazaki, Koichi Izumikawa, Katsunori Yanagihara, Yoshitsugu Miyazaki, Hiroshi Mukae and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Infection and immunity, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. The Role of Innate Immunity in Pulmonary Infections.BioMed research international · 2021
    Review
  5. UnderstandingCells · 2020
    Review
  6. Article
  7. Anemoside B4 protects againstChinese medicine · 2020
    Article
  8. Article
  9. Mechanisms and Targeted Therapies for Pseudomonas aeruginosa Lung Infection.American journal of respiratory and critical care medicine · 2018
    Review
  10. Elevated prostaglandin EMucosal immunology · 2018
    Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Shigeki NakamuraDepartment of Respiratory Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan shigekinak@nih.go.jp.
Naoki IwanagaDepartment of Respiratory Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Masafumi SekiDivision of Respiratory Medicine and Infectious Control Measures Room, Tohoku Pharmaceutical University Hospital, Sendai, Japan.
Kenji FukudomeDepartment of Life Science, Saga University Organization for General Education, Saga, Japan.
Kazuhiro OshimaDepartment of Respiratory Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Taiga MiyazakiDepartment of Respiratory Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Koichi IzumikawaUnit of Molecular Microbiology and Immunology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Katsunori YanagiharaDepartment of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
Yoshitsugu MiyazakiDepartment of Chemotherapy and Mycoses, National Institute of Infectious Diseases, Tokyo, Japan.
Hiroshi MukaeDepartment of Respiratory Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Shigeru KohnoDepartment of Respiratory Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Nagasaki University · JPNagasaki University Hospital · JPNational Institute of Infectious Diseases · JPSaga University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic lower respiratory tract infection with Pseudomonas aeruginosa is difficult to treat due to enhanced antibiotic resistance and decreased efficacy of drug delivery to destroyed lung tissue. To determine the potential for restorative immunomodulation therapies, we evaluated the effect of Toll-like receptor 4 (TLR4) stimulation on the host immune response to Pseudomonas infection in mice. We implanted sterile plastic tubes precoated with P. aeruginosa in the bronchi of mice, administered the TLR4/MD2 agonistic monoclonal antibody UT12 intraperitoneally every week, and subsequently analyzed the numbers of viable bacteria and inflammatory cells and the levels of cytokines. We also performed flow cytometry-based phagocytosis and opsonophagocytic killing assays in vitro using UT12-treated murine peritoneal neutrophils. UT12-treated mice showed significantly enhanced bacterial clearance, increased numbers of Ly6G(+) neutrophils, and increased concentrations of macrophage inflammatory protein 2 (MIP-2) in the lungs (P < 0.05). Depletion of CD4(+) T cells eliminated the ability of the UT12 treatment to improve bacterial clearance and promote neutrophil recruitment and MIP-2 production. Additionally, UT12-pretreated peritoneal neutrophils exhibited increased opsonophagocytic killing activity via activation of the serine protease pathway, specifically neutrophil elastase activity, in a TLR4-dependent manner. These data indicated that UT12 administration significantly augmented the innate immune response against chronic bacterial infection, in part by promoting neutrophil recruitment and bactericidal function.

Indexed as

AnimalsAntibodies, MonoclonalBacterial LoadCD4-Positive T-LymphocytesChronic DiseaseCytokinesDisease Models, AnimalFemaleImmunity, InnateMiceMice, KnockoutMicrobial ViabilityNeutrophilsOpsonin ProteinsPhagocytosisPneumonia, BacterialAntibodies, MonoclonalCytokinesOpsonin ProteinsSerine ProteasesToll-Like Receptor 4

Identifiers

PMID27091927
PMCPMC4936359
OpenAlexW2340859631

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.